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1. Introduction 
Bladder cancer is the second most common tumor of the urogenital tract. Urothelial 
carcinoma is the most frequent histologic type, being unique among epithelial carcinomas in 
its divergent pathways of tumorigenesis. Surgery continues to have a predominant role in 
the management of urothelial bladder cancer (Kaufman et al., 2009). However, the debate 
about the best treatment approach for T1G3 and muscle invasive tumors continually 
challenges all urologic surgeons and oncologists. This debate involves several aspects. First, 
a significant number of T1G3 tumors recurs and progresses rapidly after transurethral 
resection and BCG treatment (Wiesner et al., 2005). Second, half of patients with invasive 
tumors have a dismal outcome despite an effective treatment by radical cystectomy 
(Sternberg et al., 2007). Third, the extension of lymphadenectomy remains an issue of 
controversy, although clinical evidence suggests that an extended lymph node dissection 
may not only provide prognostic information, but also a significant therapeutic benefit for 
both lymph node-positive and lymph node-negative patients undergoing radical cystectomy 
(May et al., 2011). In muscle invasive bladder cancer, the presence of tumor foci in lymph 
nodes is an early event in progression, and the lymphatic vessels within or in the proximity 
to the primary tumor serve as the primary conduits for tumor dissemination (Youssef et al., 
2011). Fourth, although urothelial bladder cancer is a chemo-sensitive tumor (Kaufman et 
al., 2000; von der Maase et al., 2000), adjuvant systemic chemotherapy does not reveal 
benefits (Walz et al., 2008), and neoadjuvant chemotherapy is not yet accepted as the best 
approach in invasive bladder cancer (Clark, 2009). Therefore, in order to solve the 
aforementioned problems, it is crucial to improve the knowledge about tumor 
microenvironment, regulation of cancer metabolism and neovascularization. 
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Blood and lymphatic neovascularization are essential for tumor progression and metastasis, 
by promoting oxygenation and fluid drainage, and establishing potential routes of 
dissemination (Adams and Alitalo, 2007). Therefore, the inhibition of tumor-induced 
neovascularization represents a powerful option for target therapy, in order to restrain the 
most efficient pathway of cancer spread.   
2. Angiogenesis and lymphangiogenesis: Molecular regulation of vasculature 
development 
During embryogenesis, the formation of the blood vascular system initiates by 
vasculogenesis: haemangioblasts proliferate, migrate and differentiate into endothelial cells, 
which in turn will organize a primitive vascular plexus. In parallel, angiogenesis promotes 
the remodeling and expansion of the primary capillary network, originating a hierarchical 
structure of different sized vessels that will mature into functional capillaries, veins and 
arteries (Risau, 1997). The lymphatic vascular system develops latter, when a group of blood 
endothelial cells differentiates into a lymphatic endothelium that subsequently sprouts to 
form the primary lymph sacs. By lymphangiogenesis, the lymphatic endothelial cells from 
the lymph sacs will further sprout, originating the peripheral lymphatic system (Sabin, 1902, 
as cited by Oliver & Detmar, 2002). 
During postnatal life, blood and lymphatic vascular systems are, normally, in a quiescent 
state. Physiological angiogenesis and/or lymphangiogenesis occur to maintain or restore the 
integrity of tissues, namely during wound healing and the ovarian cycle. Conversely, the 
neovascularization machinery may be activated in pathological processes such as cancer and 
inflammatory diseases (reviewed in Lohela et al., 2009).  
Similarly to physiological neovascularization, tumor-induced angiogenesis and/or 
lymphangiogenesis occur to satisfy the metabolic demands of a new tissue ― the 
malignant tissue. Therefore, the molecular factors involved in the formation of the 
vascular systems during embryogenesis are newly recruited by the growing tumor 
(Papetti & Herman, 2002). 
2.1 From angiogenesis to lymphangiogenesis in the embryo 
The proliferation, sprouting and migration of endothelial cells during vasculogenesis and 
angiogenesis is mainly guided by the vascular endothelial growth factor (VEGF) signaling 
through VEGF receptor-2 (VEGFR-2) (Risau, 1997). 
VEGF (or VEGF-A), initially termed as vascular permeability factor (VPF) (Senger et al., 
1983), is a specific mitogen and pro-survival factor for blood endothelial cells, also 
stimulating vascular permeability. It binds and activates two tyrosine kinase receptors 
primarily found on the blood endothelium: VEGFR-1 (or Flt-1, fms-like tyrosine kinase 1) 
and VEGFR-2 (or KDR/Flk-1, human kinase insert domain receptor/mouse foetal liver 
kinase 1) (reviewed in Carmeliet, 2005). Interaction of VEGF with VEGFR-1 negatively 
regulates vasculogenesis and angiogenesis during early embryogenesis (Fong et al., 1999). 
On the contrary, VEGFR-2 is the earliest marker for endothelial cell development: mouse 
embryos lacking VEGFR-2 die at embryonic day 8.5-9.5 due to no development of blood 
vessels as well as very low hematopoiesis (Shalaby et al., 1995). Regarding the ligand, 
even heterozygote mice for Vegf deficiency die at embryonic day 11-12: blood islands, 
endothelial cells and vessel-like tubes fail to develop (Carmeliet et al., 1996; Ferrara et al., 
1996). 
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In humans, five weeks after fertilization, certain blood endothelial cells become responsive 
to lymphatic inducing-signals. The lymphatic vessel endothelial hyaluronan receptor-1 
(LYVE-1), a CD44 homologous transmembrane protein, is the first marker of lymphatic 
endothelial commitment.  Initially, it is evenly expressed by the blood endothelium of the 
cardinal vein, which causes the blood endothelium to acquire the ability to differentiate in 
lymphatic endothelium (Banerji et al., 1999). The polarized expression of the prospero 
related homeobox gene-1 (Prox-1) transcription factor in a subpopulation of blood 
endothelial cells determines the establishment of the lymphatic identity and initiates the 
formation of the lymphatic vascular system. In mice, Prox-1 expressing cells are first 
observed at embryonic day 10 in the jugular vein (Wigle & Oliver, 1999). Prox1 deletion 
leads to a complete absence of the lymphatic vasculature (Wigle et al., 2002). The expression 
of the transcription factor Sox18 [SRY (sex determining region Y) box 18] acts as a molecular 
switch to induce differentiation of lymphatic endothelial cells: it activates Prox-1 
transcription by binding to its proximal promoter. Sox18-null embryos show a complete 
blockade of lymphatic endothelial cell differentiation (François et al., 2008). Later, the 
sprouting, migration and survival of the newly formed lymphatic endothelial cells depends 
on the expression of VEGF-C by the mesenchymal cells surrounding the cardinal veins 
(Karkkainen et al., 2004) (Fig. 1).  
VEGF-C, like VEGF, is a member of the VEGF family of growth factors and a mitogen for 
lymphatic endothelial cells. VEGF-D is also a pro-lymphangiogenic factor, although its 
deletion does not affect the development of the primitive lymphatic vessels (Baldwin et al. 
2001). Conversely, in Vegfc-/- mice, Prox-1 positive cells appear in the cardinal veins, but fail 
to migrate and proliferate to form primary lymph sacs (Karkkainen et al., 2004). VEGF-C 
and VEGF-D interact with VEGFR-3 (of Flt-4, fms-like tyrosine kinase 4). Their affinity to 
VEGFR-3 is increased by proteolytic cleavage; the fully processed forms can also bind to 
VEGFR-2 (reviewed in Lohela et al., 2009). 
VEGFR-3 is widely expressed at the early stages of embryonic blood vasculature, becoming 
virtually restricted to lymphatic endothelium in the later stages of embryonic development, 
(after the lymphatic commitment mediated by Prox-1 expression), and during adult life 
(Kaipainen et al., 1995). In mice, inhibition of VEGFR-3 expression at embryonic day 15 
induces regression of the developing lymphatic vasculature by apoptosis of lymphatic 
endothelial cells (Makinen et al., 2001). 
The subsequent development of the lymphatic vasculature involves the separation of the 
blood and lymphatic vascular systems, the maturation of lymphatic vessels and the 
formation of secondary lymphoid organs. The molecular regulation of these processes 
involves the coordinated expression of distinct genes from those involved in the early 
events of lymphangiogenesis (reviewed in Alitalo et al., 2005) (Fig. 1). Moreover, several 
other growth factors, namely cyclooxygenase-2 (COX-2) fibroblast growth factor-2 (FGF-
2), hepatocyte growth factor (HGF), insulin-like growth factors (IGFs) and platelet-
derived growth factor-B (PDGF-B) have been shown to induce lymphangiogenesis and/or 
angiogenesis in experimental models (reviewed in Cao, 2005). These are mainly protein 
tyrosine kinases, which play central roles in signal transduction networks and regulation 
of cell behavior. In the lymphatic endothelium, these tyrosine kinases are collectively 
involved in processes such as the maintenance of existing lymphatic vessels, growth and 
maturation of new vessels and modulation of their identity and function (Williams et al., 
2010). 
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Fig. 1. Model for the development of mouse lymphatic vasculature (E- embryonic day; Syk- 
protein-tyrosine kinase SYK; Slp76- SH2 domain-containing leucocyte protein, 76-kDa; 
Ang2- angiopoietin 2; Foxc2- Forkhead Box C2) (adapted by permission from © 2005 Nature 
Publishing Group. Originally published in Nature. 438: 946-953) 
2.2 Promotion of angiogenesis and lymphangiogenesis in the malignancy context 
The major cause of cancer mortality is the metastatic spread of tumor cells that can occur via 
multiple routes, including blood and lymphatic vasculatures. For metastasis to occur, 
selected clones of malignant cells must be able to invade the newly formed vessels and 
disseminate. Induction of angiogenesis and/or lymphangiogenesis is, therefore, one of the 
first steps of the metastatic cascade (Alitalo & Carmeliet, 2002; Tobler & Detmar, 2006). 
During the pre-vascular phase, the malignant tumor remains small (up to 1 or 2 mm3); the 
preexistent surrounding blood vessels ensure the supply of oxygen and nutrients necessary 
for its survival. However, the expansion of the tumor mass is angiogenesis-dependent. As a 
compensatory response to hypoxia, proangiogenic factors such as VEGF are released by the 
malignant cells and infiltrating immune cells, namely monocytes. As a result, angiogenesis 
occurs and the tumor acquires its own blood supply. Neoplastic growth is thus promoted, as 
well as the potential for invasion and haematogenic metastasis (Kerbel, 2000). 
Vegf is upregulated in hypoxia via the oxygen sensor hypoxia-inducible factor (HIF)-1 (Pugh 
& Ratcliffe, 2003). Another recently described VEGF activation mechanism is the induction of 
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the transcriptional coactivator peroxisoma proliferator-activated receptor-gamma coactivator-
1 (PGC-1) in response to the lack of nutrients and oxygen (Arany et al., 2008). Additionally, 
VEGF gene expression can be upregulated by oncogene signaling, several growth factors, 
inflammatory cytokines and hormones (reviewed in Ferrara, 2004). Tumor cells secrete VEGF 
mainly in a paracrine manner, although it can also act in an autocrine manner to promote a 
protective/survival effect to endothelial cells, among other cell types (Brusselmans et al., 2005). 
The mechanisms underlying tumor lymphangiogenesis are not clearly defined. Inflammation 
seems to promote lymphatic neovascularization: inflammatory cells that infiltrate in the 
growing tumor produce lymphangiogenic growth factors. Another lymphangiogenesis trigger 
mechanism may be the high interstitial pressure generated inside the tumors due to the 
excessive production of interstitial fluid (reviewed in Cao, 2005). On the other hand, the 
extracellular matrix is of central importance for the generation of new lymphatic vessels as a 
response to the pathological stimulus. Integrins, a superfamily of cell adhesion molecules, are 
able to influence cell migration: integrin 91 is a target gene for Prox1, and its direct binding 
to VEGF-C and VEGF-D stimulates cell migration (reviewed in Wiig, 2010). 
VEGF-C and VEGF-D, via signaling through VEGFR-3, appear to be essential for tumor-
associated lymphangiogenesis, leading to lymphatic vessel invasion, lymph node 
involvement and distant metastasis (reviewed in Achen & Stacker, 2008). Moreover, VEGF 
interaction with VEGFR-2 may also promote lymphatic neovascularization, namely inside 
the regional draining lymph nodes, even before lymph node metastasis occurrence. This 
probably corresponds to a pathophysiologic strategy of “soil” preparation by the primary 
tumor to ensure the success of its future dissemination (Hirakawa et al., 2005). In fact, 
sentinel lymph node metastasis is the first step in the spreading of many cancer types. 
Preexisting blood and lymphatic vessels in the vicinity of the malignant mass may 
contribute to tumor spread. However, de novo formed vessels by tumor-induced 
angiogenesis and lymphangiogenesis seem to be the preferential routes for dissemination 
(reviewed in Cao, 2005). This is a consequence of the ultra-structure of the tumor-associated 
blood and lymphatic vessels. 
2.3 Ultra-structure of tumor-associated blood and lymphatic vessels 
Blood vessels present in malignant tissues show remarkable differences with vessels present 
in normal tissues. Tumor blood vessels are highly disorganized: they are tortuous, 
excessively branched and dilated. The basement membrane and the muscular coverage are 
incomplete or absent. The endothelial cells, abnormal in shape, overlap and are projected 
into the lumen rather than organizing a pavement layer below the basement membrane. 
Blood vessel invasion is facilitated by this aberrant structure, but the extravasation rate is 
high, and blood flow is variable. As a result, interstitial tumor hypertension occurs, and 
delivery of therapeutic agents into tumors is compromised (Jain & Carmeliet, 2001; 
reviewed in Cao, 2005). The intratumoral edema is pernicious to malignant cells; therefore, 
homeostasis needs to be re-established. The formation of a tumoral lymphatic vasculature 
could potentially resolve this problem. 
The key function of lymphatic vessels is to collect the excessive amount of interstitial fluid 
back to the blood circulation for immune surveillance in lymph nodes. Unlike normal blood 
capillaries, lymphatic capillaries have a discontinuous or fenestrated basement membrane and 
are not ensheathed by pericytes or smooth muscle cells; the endothelial cells are arranged in a 
slightly overlapping pattern and lack tight interendothelial junctions. Specialized anchoring 
www.intechopen.com
 
Bladder Cancer – From Basic Science to Robotic Surgery 
 
92
filaments of elastic fibers connect the endothelial cells to the extracellular matrix, which causes 
the vessels to dilate rather than to collapse when hydrostatic pressure rises (Alitalo et al., 2005; 
Tobler & Detmar, 2006). This structure facilitates the collection of interstitial fluid and is ideal 
for malignant cells’ entry into the lymphatic flow. 
A highly debated question is whether there are functional lymphatic vessels inside tumors 
(reviewed in Alitalo & Carmeliet, 2002; reviewed in Detmar & Hirakawa, 2002). On one 
hand, the elevated interstitial pressure generated by the proliferation of the malignant cells 
and by the high extravasion rate compromises the infiltration of new lymphatic vessels in 
the tumor stroma. Although intratumoral lymphangiogenesis may occur, the newly formed 
vessels are compressed and nonfunctional (Jain & Fenton, 2002). To compensate the lack of 
an intratumoral draining mechanism, the peritumoral lymphatic vessels enlarge due to an 
excess of pro-lymphangiogenic factors in that area. Therefore, in this model, the peritumoral 
lymphatic vessels passively collect interstitial fluid and, eventually, malignant cells 
(Carmeliet & Jain, 2000) (Fig. 2, A). However, some studies have demonstrated a 
relationship between the existence of functional intratumoral lymphatics, with cycling 
lymphatic endothelial cells and tumor emboli, and lymph node involvement (reviewed in 
Da et al., 2008). Additionally, peritumoral lymphangiogenesis occurs, and the new vessels 
actively contribute to metastatic spread (Padera et al., 2002) (Fig. 2, B). Probably, there are 
some organ-specific determinants that influence the occurrence of peritumoral and/or 
intratumoral lymphangiogenesis, as well as the function of the newly formed vessels. 
2.4 Lymphovascular invasion and metastasis   
Tumor metastasis involves a coordinated series of complex events that include promotion of 
angiogenesis and lymphangiogenesis, detachment of malignant cells from the primary 
tumor, microinvasion of the surrounding stroma, blood and/or lymphatic vessel invasion, 
survival of the malignant cells in the blood and/or lymphatic flow, and extravasion and 
growth in secondary sites. Because the large lymphatic vessels reenter the blood vascular 
system, malignant cells spread via the lymphatic system to the regional lymph nodes and, 
from this point, to distant organs (Alitalo & Carmeliet, 2002; Tobler & Detmar, 2006) (Fig. 3). 
Follow-up data have shown that 80% of the tumors, mainly those of epithelial origin, 
disseminate through the lymphatic vasculature; the remaining 20% use the blood circulation 
to colonize secondary organs (reviewed in Saharinen et al., 2004; reviewed in Wilting et al., 
2005). 
The blood vessels are not the best route for the success of malignant dissemination. 
Although their disorganized structure may contribute to the intravasion of malignant cells 
or emboli, in the bloodstream these cells experience serum toxicity, high shear stresses and 
mechanical deformation. Consequently, the viability of the tumor cells is seriously 
compromised (reviewed in Swartz, 2001). Conversely, the success rate of lymphogenous 
spread is high. As previously referred, the structure and function of the lymphatic 
capillaries facilitates intravasion of tumor cells or emboli. On the other hand, the 
composition of the lymph is similar to interstitial fluid, which provides an optimal medium 
for the survival of malignant cells. In collecting lymphatic vessels, muscle fibers assure 
lymph propulsion, that flows slowly, and valves prevent its backflow. Lymph nodes are 
areas of flow stagnation that represent ideal “incubators” for malignant cells’ growth. Some 
cells exit the lymph node through the efferent channels or high endothelial venules.  
Other cells may remain mechanically entrapped for long periods of time, originating 
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Fig. 2. (A) Traditional model of tumor metastasis via lymphatic and blood vessels. (B) Active 
lymphangiogenesis model of tumor metastasis (reprinted by permission from © 2002 
Rockefeller University Press. Originally published in J. Exp. Med. 196: 713-718) 
 
 
 
Fig. 3. Pathways of dissemination of malignant cells (reprinted by permission from © 2008 
John Wiley & Sons, Inc. Originally published in Ann. N. Y. Acad. Sci. 1131: 225-234) 
A B 
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micrometastases (Swartz, 2001; Van Trapen & Pepper, 2002). Martens and colleagues 
described the expression of a gene signature of scavenger and lectin-like receptors in the 
lymph node sinus, which are known mediators of tumour cell adhesion and, therefore, can 
contribute to selective metastasis in an organ-specific context (Martens et al., 2006). Probably, 
tumor-cell-specific characteristics, microenvironmental factors and crosstalk between tumor 
and host cells have a pivotal role in determining survival and growth of micrometastasis. 
Moreover, lymph node lymphangiogenesis may provide an additional mechanism to facilitate 
further metastatic spread throughout the lymphatic system (Ji, 2009). The occurrence of 
lymphangiogenesis prior to arrival of tumor cells indicates that signals derived from the 
primary tumor are transported to the draining lymph nodes (Hirakawa et al., 2005). 
Different tumors metastasize preferentially to different organs, suggesting that tumor 
spread is a guided process. It has been reported that malignant cells may use chemokine 
receptor ligand interactions to guide the colonization of target organs (reviewed in 
Saharinen et al., 2004; reviewed in Achen & Stacker, 2008). Chemokines are a family of 
chemoattractant cytokines that bind to G protein-coupled receptors expressed on target 
cells, namely malignant cells (Laurence, 2006). For instance, breast cancer cells, that 
normally choose regional lymph nodes, bone marrow, lung and liver as their first sites of 
destination, overexpress CCR7 (chemokine, CC motif, receptor 7) and CXCR4 (chemokine, 
CXC motif, receptor 4). Their ligands, SLC/CCL2 (secondary lymphoid chemokine / CC-
type chemokine ligand 21) and SDF-1 CXCL12/ (stromal cell-derived factor 1 / chemokine, 
CXC motif, ligand 12) are expressed at high levels by isolated lymphatic endothelial cells 
and lymphatic endothelium from vessels present in the preferred sites of metastasis (Muller 
et al., 2001). This guides chemoattraction and migration of tumor cells, and characterizes 
lymphatic vessel invasion as an active event. 
3. Angiogenesis, lymphangiogenesis and lymphovascular invasion in 
urothelial bladder cancer  
The metastatic profile of urothelial bladder carcinoma implies, as in most malignant tumors, 
the dissemination of tumor cells through the lymphatic vasculature, and the colonization of 
regional lymph nodes is an early event in progression. Smith & Whitmore reported the 
involvement of the internal iliac and obturator groups of lymph nodes in about 74% of patients 
who underwent radical cystectomy; the external iliac nodes were involved in 65% of the 
patients, and the common iliac nodes were involved in 20% of the cases (Smith & Whitmore, 
1981). As already referred, controversy exists regarding the optimal extent of 
lymphadenectomy and the number of lymph nodes to be retrieved at radical cystectomy. An 
extended pelvic lymph node dissection (encompassing the external iliac vessels, the obturator 
fossa, the lateral and medial aspects of the internal iliac vessels, and at least the distal half of 
the common iliac vessels together with its bifurcation) has been suggested as potentially 
curative in patients with metastasis or micrometastasis to a few nodes (Karl et al., 2009; Abol-
Enein et al., 2011). Wright and colleagues observed that an increased number of lymph nodes 
removed at the time of radical cystectomy associates with improved survival in patients with 
lymph node-positive bladder cancer (Wright et al., 2008). The recommendation from the 
Bladder Cancer Collaboration Group is that ten to fourteen lymph nodes should be removed 
at the time of radical cystectomy (Herr et al., 2004). The concept of lymph node density (the 
number of positive lymph nodes divided by the total number of lymph nodes) was introduced 
by Stein and colleagues and helps to select lymph node-positive patients after radical 
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cystectomy for adjuvant treatment (Stein et al., 2003). However, the lymph node density 
threshold is a debatable question (Gilbert, 2008). In large series, the median number of total 
lymph nodes removed was nine, with high lymph node density (25%), which can lead to 
misleading N0 staging (Wright et al., 2008). Therefore, in this subgroup of patients (lymph 
nodes removed ≤ 9 and N0), another prognostic factor is needed to better select patients for 
adjuvant treatment. Moreover, according to Malmström, extending the boundaries of surgery 
will not drastically improve survival. The focus should be on exploring biomarkers that 
predict extravesical dissemination and improving on the systemic treatment concept 
(Malmström, 2011). In this line of investigation, angiogenesis, lymphangiogenesis and 
lymphovascular invasion occurrence have been implicated in bladder cancer progression, 
invasion and metastasis, and represent potential targets for guided therapy. 
Several studies reported a significant association between VEGF overexpression ― both in 
tumor tissue (Crew et al., 1997; O’Brien et al., 1995) and urine (Crew et al., 1999; Jeon et al., 
2001) ―, high blood vessel density (Goddard et al., 2003; Santos et al., 2003) and the 
occurrence of recurrence and progression in patients with non-muscle invasive bladder 
cancer. In this group of patients, it has been observed that angiotensin II type 1 receptor 
(AT1R) expression associates with high blood vessel density and is related to early 
intravesical recurrence (Shirotake et al., 2011). AT1R supports tumor-associated macrophage 
infiltration, which results in enhanced tissue VEGF protein levels (Egami et al., 2009). These 
results suggest that AT1R is involved in bladder tumor angiogenesis and may become a new 
molecular target and a prognostic factor for urothelial bladder cancer patients  
In the subset of invasive urothelial bladder cancer, most studies also reported the 
association between angiogenesis occurrence and unfavorable prognosis. High blood vessel 
density was identified as an independent prognostic factor by several authors (Bochner et 
al., 1995; Chaudhary et al., 1999; Dickinson et al., 1994; Jaeger et al., 1995). Moreover, 
overexpression of VEGF associates with high blood vessel density (Sato et al., 1998; Yang et 
al., 2004). Analysis of serum levels of VEGF has demonstrated its optimal sensitivity and 
specificity for predicting metastatic disease (Bernardini et al., 2001). Inoue and colleagues 
reported the importance of measuring blood vessel density and VEGF immunoexpression in 
identifying patients with invasive tumors who are at high risk of recurrence and 
development of metastasis after radical cystectomy and neoadjuvant systemic 
chemotherapy. The author highlighted the role of VEGF as a cell survival factor, not only by 
protecting the malignant cells in situations of hypoxia, but also during the occurrence of 
chemotherapy-induced apoptosis (Inoue et al., 2000). 
Beyond VEGF signaling, other angiogenesis-related molecules have been implicated in 
bladder cancer recurrence, progression and metastasis, namely several proangiogenic 
factors ― matrix metalloproteinases, fibroblast growth factors, platelet derived-growth 
factors, cyclooxygenases, integrins, angiopoietins, Notch signaling ― and several 
antiangiogenic factors ― thrombospondin-1, angiostatin-endostatin, platelet factor-4 
(Chikazawa et al., 2008; Durkan et al., 2001; Grossfeld et al., 1997;  Patel et al., 2006; reviewed 
in Pinto et al., 2010; Shariat et al., 2010). 
The relevance of lymphangiogenesis in bladder cancer setting has gained recent attention. A 
few articles suggest that lymphangiogenesis occurrence, detected using specific lymphatic 
markers, is associated with poor prognosis (Fernández et al., 2008; Ma et al., 2010; Miyata et 
al., 2006; Zhou et al., 2011; Zu et al., 2006). VEGF-C, VEGF-D and VEGFR-3 are 
overexpressed in bladder cancer and promote tumor-induced lymphangiogenesis. This 
correlates with tumor upstaging and lymph node involvement, and results in a worse 
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prognosis (Afonso et al., 2009; Miyata et al., 2006; Suzuki et al., 2005; Herrmann et al., 2007; 
Zhou et al., 2011; Zu et al., 2006). Interestingly, VEGF-C overexpression also associates with 
angiogenic events, probably by interaction of the fully processed form with VEGFR-2 
(Afonso et al., 2009; Miyata et al., 2006). On the other hand, tumor associated macrophages 
play an important role in promoting lymphangiogenesis by producing VEGF-C and VEGF-
D, mainly in peritumoral areas (Schoppmann et al., 2002). The blockade of VEGF-C/D with 
a soluble VEGF receptor-3 markedly inhibited lymphangiogenesis and lymphatic metastasis 
in an orthotopic urinary bladder cancer model. In addition, the depletion of tumor 
associated macrophages exerted similar effects (Yang et al. 2011). 
Lymphovascular invasion has been identified as an independent prognostic factor for bladder 
cancer patients in several studies (Cho et al., 2009; Leissner et al., 2003; Lotan et al., 2005; Quek 
et al., 2005). In patients with newly diagnosed T1 urothelial bladder cancer, lymphovascular 
invasion in transurethral resection of bladder tumor specimens predicts disease progression 
and metastasis (Cho et al., 2009). Lotan and colleagues observed that blood and lymphatic 
vessel invasion (accessed by Haematoxylin-eosin stain) is an independent predictor of 
recurrence and low overall survival in patients who undergo radical cystectomy for invasive 
urothelial bladder cancer and are lymph node negative. They emphasized that these patients 
represent a high risk group that may benefit from neoadjuvant or adjuvant treatments. 
However, in this study, the mean number of lymph nodes removed per patient at the time of 
radical cystectomy was 20,1±10,2 (Lotan et al., 2005). 
The prognostic impact of lymphovascular invasion in patients with lymph node-negative 
urothelial bladder cancer treated by radical cystectomy has been recently validated in large 
multicentre trials (Bolenz et al., 2010; Shariat et al, 2010). May and colleagues emphasized that, 
besides the importance of performing extended lymphadenectomies, the information resulting 
from an assessment of lymphovascular invasion is critical for stratification of risk groups and 
identification of patients who might benefit from adjuvant treatments (May, 2011). Algaba 
underlined that, in this field, it would be necessary to reach a consensus on strict diagnostic 
criteria as soon as possible, to be able to incorporate this prognostic factor in clinical practice 
(Algaba, 2006). Leissner and colleagues endorsed that blood and lymphatic vessel invasion 
should be commented on separately in the pathology report (Leissner et al., 2003). 
Afonso and colleagues reported the prognostic contribution of molecular markers of blood 
vessels (like CD31) (Fig. 4, A) and lymphatic vessels (like D2-40) (Fig. 4, B) to accurately 
assess the occurrence of blood and/or lymphatic vessel invasion. The use of endothelial 
markers is encouraged because immunohistochemistry antibodies are significantly more 
sensitive in detecting invasive events than the standard Haematoxylin-eosin staining 
method and, additionally, facilitate the discrimination between blood and lymphatic vessel 
invasion. This is particularly important in identifying isolated malignant cells invading 
lymphatic vessels, because their viability is more probable in the lymphatic flow than in the 
blood circulation. Conversely, emboli of malignant cells are better suited to survive in the 
bloodstream, and are more easily identified, even by the traditional Haematoxylin-eosin 
staining method. This advocates the use of lymphatic markers for purposes of counting 
invaded lymphatic vessels. In this study, blood vessel invasion by malignant emboli 
assessed by CD31 staining (Fig. 5, A), and lymphatic vessel invasion by isolated malignant 
cells assessed by D2-40 staining (Fig. 5, B) significantly affected patients’ prognosis; blood 
vessel invasion remained as an independent prognostic factor (Afonso et al., 2009). When 
included in a model of bladder cancer aggressiveness, these parameters contributed to a 
clear separation between low and high aggressiveness groups (Afonso et al., 2011).  
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Fig. 4. Intratumoral blood vessels highlighted by CD31 (A), and intratumoral lymphatic 
vessels highlighted by D2-40 (B), in invasive urothelial bladder carcinoma. Evidence of 
internal negative control in A (D2-40 negative blood vessel ) (original magnification x100) 
(reprinted by permission from © 2009 John Wiley & Sons, Inc. Originally published in 
Histopathol. 55: 514-524) 
Both peritumoral and intratumoral lymphatic vessels seem to be functional for urothelial 
cells’ dissemination. Some articles reported the existence of intratumoral lymphatic 
vessels in bladder tumors, and their possible participation in metastatic events. No 
intratumoral edema has been observed, which is consistent with the occurrence of 
efficient lymphatic neovascularization (Afonso et al., 2009; Fernández et al., 2008; Ma et 
al., 2010; Miyata et al. 2006). Lymphatic vessel invasion occurrence correlates with high 
lymphatic vessel density values, mainly in the intratumoral areas. Although most of the 
invaded lymphatic vessels were distorted and collapsed, single malignant cells were 
significantly observed in the well-preserved intratumoral lymphatic vessels (Fig. 5, B). 
Moreover, the absence of intratumoral edema is a surrogate marker of an efficient 
lymphatic flow (Afonso et al., 2009). 
 
  
Fig. 5. Intratumoral blood vessel highlighted by CD31 invaded by a small malignant 
embolus (A), and intratumoral lymphatic vessel highlighted by D2-40 invaded by an 
isolated malignant cell (B), in invasive urothelial bladder carcinoma (original magnification 
x100) (reprinted by permission from © 2009 John Wiley & Sons, Inc. Originally published in 
Histopathol. 55: 514-524) 
A B

A B 
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4. Angiogenesis and Lymphangiogenesis as therapeutic targets in urothelial 
bladder cancer  
Our current understanding of the importance of tumor-induced angiogenesis and 
lymphangiogenesis for the occurrence of haematogenous and lymphogenous metastasis 
suggests that, by blocking the activity of key molecules involved in these processes, it 
should be possible to suppress the onset of metastasis following diagnosis of cancer and its 
subsequent therapy. Moreover, prophylactic suppression of metastasis would be useful for 
patients who are at risk of recurrence (Thiele & Sleeman, 2006). Therefore, clinical trials 
evaluating novel agents and combinations including chemotherapeutic drugs, as well as 
targeted inhibitors, are desperately needed (Iyer et al., 2010). 
Two types of neovascularization inhibitors have been described. The direct inhibitors refer 
to compounds that function directly on endothelial cells by blocking a common pathway of 
vessel growth. Indirect inhibitors are molecules that neutralize the functions of angiogenic 
and lymphangiogenic growth factors; due to their mode of action, these are preferred over 
the direct inhibitors (Cao, 2005; Folkman, 2003). The main strategies that have been tested 
focus on modulating the signaling of VEGF family of growth factors and receptors, and are 
based on the use of monoclonal antibodies or soluble versions of receptors to neutralize the 
ligand-receptor interaction, and the inhibition of the kinase activity of the receptors (Achen 
et al., 2006; Thiele & Sleeman, 2006).  
In 2004, the U.S. Food and Drug Administration (FDA) has approved bevacizumab 
(Avastin®), a humanized monoclonal antibody that binds to VEGF-A, as the first drug 
developed solely for antiangiogenesis anticancer use in humans. Antiangiogenic drugs are 
presently approved in a wide number of tumor types, namely in breast, colorectal, lung, 
liver, glioblastoma and kidney cancer. Other compounds are currently in preclinical 
development, with many of them now entering the clinic and/or achieving approval 
(reviewed in Boere et al., 2010; reviewed in Cook & Figg, 2010; reviewed in Pinto et al., 
2010).  
In anticancer therapy, an angiogenesis inhibitor may prevent the growth of new blood 
vessels. This should decrease the delivery of oxygen and nutrients – the “starving therapy” – 
which are indispensable elements for the support of uncontrolled cell division and tumor 
expansion. Angiogenesis inhibitors are predicted to be cytostatic, stabilizing tumors and 
perhaps preventing metastasis, rather than being curative (Zhi-chao & Jie, 2008). Therefore, 
there is the need to administrate this type of therapy for long periods of time. As a 
consequence, problems with bleeding, blood clotting, heart function and depletion of the 
immune system are common (Cohen et al., 2007). Nevertheless, inhibition of circulating 
VEGF reduces vascular permeability and thus tumoral interstitial pressure, permitting 
easier penetration of the tumor by conventional chemotherapeutic targets (Ferrara, 2005). 
A second concern of anti-angiogenesis therapy is the approach to objectify the response to 
anti-angiogenic drugs. Chan and colleagues found that targeted contrast enhanced micro-
ultrasound imaging enables investigators to detect and monitor vascular changes in 
orthotopic bladder tumors. Therefore, this technique may be useful for direct, noninvasive 
and in vivo evaluation of angiogenesis inhibitors (Chan et al., 2011). Lassau and colleagues 
demonstrated that dynamic ultrasound can be used to quantify dynamic changes in tumor 
vascularity as early as three days after the administration of the anti-angiogenic drug. These 
changes may be potential surrogate measures of the effectiveness of antiangiogenic therapy, 
namely by predicting progression-free survival and overall survival (Lassau et al., 2011). 
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Regarding antilymphangiogenic strategies, numerous compounds that could be used to 
block lymphangiogenesis already exist, although there is some delay in the translation to the 
clinic. These act mainly by targeting lymphangiogenic protein tyrosine kinases (Williams et 
al., 2010) (Table 1) or other indirect regulators of lymphangiogenic events. For instance, 
rapamycin (sirolimus), a classical immunosuppressant drug used to prevent rejection in 
organ transplantation, and a known inhibitor of the mTOR (mammalian target of 
rapamycin) signaling, has demonstrated potent antilymphangiogenic properties (Huber et 
al., 2007), and may suppress lymphatic metastasis (Kobayashi et al., 2007). mTOR is a 
member of the phosphoinositide-3-kinase-related kinase family, and is centrally involved in 
growth regulation, proliferation control and cancer cell metabolism (Rosner et al., 2008). Its 
inhibition impairs downstream signaling of VEGF-A as well as VEGF-C via mTOR to the 
ribosomal p70S6 kinase (a regulator of protein translation, and a major substrate of mTOR) 
in lymphatic endothelial cells (Huber et al., 2007). Other derivative compounds of 
rapamycin, like everolimus (RAD001) and temsirolimus (Torisel), have also demonstrated 
anti-tumor properties, namely by inhibiting tumor neovascularization (reviewed in Garcia & 
Danielpour, 2008). Recently, in patients with lymphangioleiomyomatosis (LAM, a 
progressive, cystic lung disease in women, which is associated with inappropriate activation 
of mTOR) sirolimus stabilized lung function, reduced serum VEGF-D levels, and was 
associated with a reduction in symptoms and improvement in the quality of life 
(McCormack et al., 2011).  
Inhibition of lymphangiogenesis has been shown to block lymphatic metastasis by 50-70% in 
preclinical animal models, with good safety profiles, which suggests that anti-
lymphangiogenic therapy could possibly be used safely in cancer patients, without 
disrupting normal lymphatic function (reviewed in Holopainen et al., 2011). Optimally, the 
gold-standard strategy would be the one that could inhibit both angiogenic and 
lymphangiogenic cascades, in order to compromise the success of haematogenous and 
lymphogenous dissemination. Some potential compounds are being investigated (reviewed 
in Boere et al., 2010; reviewed in Cook & Figg, 2010; reviewed in Pinto et al., 2010; reviewed 
in Stacker & Achen, 2008). 
Urothelial bladder carcinoma has experienced very few therapeutic successes, regarding 
antineovascularization therapy, in the last years. Compounds like bevacizumab (Avastin®), 
aflibercept (VEGF-Trap, AVE0005), sunitinib malate (Sutent, SU11248), sorafenib (BAY 43-
9006), vandetanib (Zactima, ZD6474) and pazopanib (Votrient, GW786034) are being tested 
in preclinical and clinical trials (reviewed in Pinto et al., 2010) (Table 2). 
Bevacizumab, as has been already referred, is a monoclonal antibody that binds and 
neutralizes VEGF in the serum. Aflibercept is a soluble fusion protein of the human 
extracellular domains of VEGFR-1 and VEGFR-2, and the Fc portion of human 
immunoglobulin G. It binds, with a higher affinity than other monoclonal antibodies, to 
VEGF and additional VEGF-family members, namely VEGF-B and placental growth factor 
(PlGF). Sunitinib is an oral multi-targeted receptor tyrosine kinase inhibitor, with activity 
against VEGF receptors and PDGF receptors, among others. Sorafenib is a small, oral 
molecule that inhibits various targets along the EGFR/MAPK (epidermal growth factor 
receptor / mitogen-activated protein kinase) signal transduction pathway, and also through 
VEGFR and PDGFR families. Vandetanib is a tyrosine kinase inhibitor, antagonist of VEGFR 
and EGFR. Pazopanib is a multitargeted tyrosine kinase inhibitor against VEGF receptors, c-
kit, and PDGF receptors (Cook & Figg, 2010). 
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Gene Role in lymphatic vessels 
Inhibitors
available
Effect of pathway inhibition 
VEGFR-2 
Receptor for the VEGF family 
of ligands. Can also 
heterodimerize with VEGFR-3.
Yes 
Secreted VEGFR-2 is a naturally 
occurring inhibitor of lymphatic 
vessel growth; however, Sorafenib† 
did not block VEGF-C/D induced 
tumor lymphangiogenesis. 
VEGFR-3 
Predominant receptor for 
VEGF-C and VEGF-D. 
Transduces survival, 
proliferation and migration 
signals. 
Yes 
Cediranib‡ blocks VEGFR-3 activity 
and inhibits lymphangiogenesis. 
Anti-VEGFR-3 antibody prevented 
tumor lymphangiogenesis with no 
effect on preexisting vessels. 
Tie1 
Not critical for lymphatic cell 
commitment during 
development, and no ligand 
has been shown. 
None 
reported. 
Tie1 knockout mouse has lymphatic 
vascular 
abnormalities that precede the 
blood vessel 
phenotype. 
Tie2 
Receptor for Ang-1 and Ang-2. 
Appears to control vessel 
maturation. 
Yes 
Tie2-/- mice are embryonic lethal 
due to vascular defects. Inhibition 
of Ang-2 leads to tumor blood 
vessel normalization. 
EphB4 
Expressed on lymphatic 
capillary vessels. Involved in 
vascular patterning. Binds to 
the ephrinB2 ligand. 
Yes 
Mice expressing a mutant form of 
ephrinB2 lacking the PDZ binding 
domain show major lymphatic 
defects in capillary vessels and 
collecting vessel valve formation. 
FGFR3 
The ligands FGF-1 and FGF-2 
promote proliferation, 
migration, and survival of 
cultured lymphatic endothelial 
cells. FGFR3 is a direct  
transcriptional target  
of Prox1. 
Yes 
Knockdown of FGFR3 reduced 
lymphatic endothelial cells’ 
proliferation. 
IGF1R 
Both of the IGF1R ligands,  
IGF-1 and IGF-2, significantly 
stimulated proliferation  
and migration of  
primary lymphatic  
endothelial cells. 
Yes None reported. 
PDGFR 
The ligand PDGF-BB 
stimulated MAP kinase 
activity and cell motility of 
isolated lymphatic endothelial 
cells. 
Yes None reported. 
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Gene Role in lymphatic vessels 
Inhibitors
available
Effect of pathway inhibition 
MET 
The ligand for c-Met, 
hepatocyte growth factor, has 
lymphangiogenic effect, but it 
is unclear if c-Met is expressed 
on lymphatic endothelial cells.
Yes May be indirect effect. 
†Sorafenib inhibits B-Raf, PDGFRb, VEGFR-2 and c-Kit. ‡Cediranib inhibits VEGFR-1, -2, -3, PDGFRb 
and c-Kit. 
Table 1. Protein tyrosine kinases involved in lymphatic biology, and available inhibitors 
(Tie- tyrosine kinase with immunoglobulin and EGF homology domain; EphB4- ephrin 
type-B receptor 4) (reprinted by permission from © 2010 BioMed Central Ltd. Originally 
published in J. Ang. Res. 2: 1-13) 
 
Principal investigator / 
organization 
Regimen Patient population Phase 
Siefker-Radtke/MDACC 
Methotrexate + vinblastine + 
doxorubicin+ cisplatin + 
bevacizumab 
Neoadjuvant 
(muscle-invasive) 
II 
Kraft/MUSC 
Gemcitabine + cisplatin + 
bevacizumab → cystectomy → 
paclitaxel + bevacizumab 
Neoadjuvant/adjuvant  
(muscle-invasive) 
II 
Hahn/HOG 
Gemcitabine + cisplatin + 
bevacizumab 
First-line metastatic II 
Bajorin/MSKCC 
Gemcitabine + carboplatin + 
bevacizumab 
First-line metastatic  
(cisplatin-ineligible) 
II 
Rosenberg/CALGB 
Gemcitabine + cisplatin ± 
bevacizumab 
First-line metastatic III 
Garcia/Cleveland Clinic Sunitinib 
Neoadjuvant  
(muscle-invasive) 
II 
Sonpavde/HOG 
Gemcitabine + cisplatin + 
sunitinib 
Neoadjuvant  
(muscle-invasive) 
II 
Bellmunt Sunitinib 
First-line metastatic 
(cisplatin-ineligible) 
II 
Galsky/US Oncology 
Gemcitabine + cisplatin + 
sunitinib 
First-line metastatic II 
Hussain/University of 
Michigan 
Sunitinib versus placebo 
Maintenance after first-
line chemotherapy 
II 
Gallagher/MSKCC Sunitinib Second-line metastatic II 
Milowsky/MSKCC 
Gemcitabine + cisplatin + 
sorafenib 
First-line metastatic II 
Kelly/Yale 
Gemcitabine + carboplatin + 
sorafenib 
First-line metastatic 
(cisplatin-ineligible) 
II 
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Principal investigator / 
organization 
Regimen Patient population Phase 
Sternberg/EORTC 
Gemcitabine + carboplatin ± 
sorafenib 
First-line metastatic II 
Dreicer/ECOG Sorafenib Second-line metastatic II 
Choueiri/DFCI Docetaxel ± vandetanib Second-line metastatic II 
Vaishampayan/Mayo 
Clinic 
Pazopanib Second-line metastatic II 
MDACC = MD Anderson Cancer Center; MUSC = Medical University of South Carolina; HOG = 
Hoosier Oncology Group; MSKCC = Memorial Sloan-Kettering Cancer Center; CALGB = Cancer and 
Leukemia Group B; EORTC = European Organization for Research and Treatment of Cancer; ECOG = 
Eastern Cooperative Oncology Group; DFCI = Dana-Farber Cancer Institute 
Table 2. Selected ongoing or recently completed trials exploring antiangiogenic therapies in 
urothelial bladder carcinoma (reprinted by permission from © 2010 Elsevier. Originally 
published in Commun. Oncol. 7: 500-504) 
4.1 Preclinical studies 
In the preclinical scenario, Videira and colleagues studied the effect of bevacizumab on 
autocrine VEGF stimulation in bladder cancer cell lines, and concluded that, at clinical 
bevacizumab concentrations, cancer cells compensate the VEGF blockade, by improving the 
expression of VEGF and related genes. This highlights the need to follow the patient’s 
adaptation response to bevacizumab treatment (Videira et al., 2011). The antiangiogenic 
treatment of tumours may restore vascular communication and, thereby, normalize flow 
distribution in tumour vasculature. The use of antiangiogenic drugs leads to improved 
tumour oxygenation and chemotherapy drug delivery (Pries et al., 2010). However, these 
mechanisms may be also the cause of malignant dissemination, because tumours elicit 
evasive resistance. Caution is recommended, due to the divergent effects that VEGF 
inhibitors can induce on primary tumor growth and metastasis (Loges et al., 2009).  
Yoon and colleagues, when exposing six human bladder cancer cell lines to an escalating 
dose of sunitinib alone or in combination with cisplatin/gemcitabine, demonstrated that 
sunitinib malate has a potent antitumor effect and may synergistically enhance the known 
antitumor effect of gemcitabine (Yoon et al, 2011).  
The first study with vandetanib in bladder cancer cell lines demonstrated its potential to 
sensitize tumor cells to cisplatin. At vandetanib concentrations of ≤2microM, the 
combination with cisplatin was synergistic, especially when given sequentially after 
cisplatin , and additive with vandetanib followed by cisplatin (Flaig et al., 2009). 
Li and colleagues studied the efficacy of pazopanib, both alone and in combination with 
docetaxel, in bladder cancer cell lines. They demonstrated that single-agent pazopanib has 
modest activity, but when given in combination with docetaxel, acted synergistically in 
docetaxel-resistant bladder cancer cells, with the potential of improved toxicity (Li et al., 2001). 
Urothelial bladder carcinoma expresses mTOR signaling molecules, providing a rationale 
for clinical trials evaluating agents targeting this pathway (Tickoo et al., 2011). In fact, some 
studies using bladder cancer cell lines have demonstrated that sirolimus and related drugs 
inhibit the growth of cancer cells and decrease their viability (Fechner et al., 2009; Hansel et 
al., 2010; Pinto-Leite et al., 2009; Schedel et al., 2011). Similar results were obtained when 
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treating bladder cancer animal models with sirolimus or everolimus (Chiong et al., 2011; 
Oliveira et al., 2011; Parada et al., 2011; Seager et al., 2009; Vasconcelos-Nóbrega et al., 2011). 
4.2 Phase II studies 
The results of a phase II trial of cisplatin, gemcitabine, and bevacizumab  (CGB) as first-line 
therapy for metastatic urothelial carcinoma revealed that CGB may improve overall survival 
― with a median follow-up of 27.2 months, overall survival time was 19.1 months. However, 
the rate of side effects was high, namely neutropenia, thrombocytopenia, anemia, and deep 
vein thrombosis/pulmonary embolism (Hahn et al., 2011).  
In a phase II trial of gemcitabine, carboplatin, and bevacizumab in patients with 
advanced/metastatic urothelial carcinoma, Balar and colleagues concluded that addition of 
bevacizumab does not improve the response rate. However, bevacizumab can be safely 
added to gemcitabine and carboplatin, because the rate of venous thromboembolisms is 
similar to the one observed with gemcitabine and carboplatin alone (Balar et al., 2011). 
Moreover, in a pooled analysis of cancer patients in randomized phase II and III studies, the 
addition of bevacizumab to chemotherapy did not statistically significantly increase the risk 
of venous thromboembolisms versus chemotherapy alone. Probably, the risk for venous 
thromboembolisms is driven predominantly by tumor and host factors (Hurwitz et al., 
2011). This type of side effect is primarily prevented by using anticoagulants simultaneously 
with cytotoxic chemotherapy (Riess et al., 2010). However, anticoagulant use during 
bevacizumab therapy may increase the risk of serious hemorrhage, although it is generally 
well tolerated (Bartolomeo et al., 2010). This controversial issue is still under scrutiny and 
more data are needed to clarify the optimal regime to reduce venous thromboembolisms in 
bladder cancer patients, particularly in those who are being treated with antiangiogenic 
drugs.   
Patients with recurrent or metastatic urothelial carcinoma who had received a prior 
platinum-containing regimen were entered in a phase II trial with aflibercept as a second-
line therapy. Aflibercept was well tolerated, but it had limited single agent activity in 
platinum-pretreated bladder cancer patients (Twardowski et al., 2009). 
In a phase II study of sunitinib in patients with metastatic urothelial cancer designed to assess 
the efficacy and tolerability of this drug in patients with advanced, previously treated 
urothelial cancer, anti-tumour responses were observed. However, sunitinib did not achieve 
the predetermined threshold of 20% activity defined by the Response Evaluation Criteria in 
Solid Tumors, and side effects such as embolic events were reported (Gallagher et al., 2010).  
In a multicenter phase II trial with sunitinib as first-line treatment in patients with 
metastatic urothelial cancer ineligible for cisplatin, on intention-to-treat analysis revealed 
that 38% of the patients showed partial responses (PRs), and 50% presented with stable 
disease (SD), the majority more than 3 months. Clinical benefit (PR + SD) was 58%. Median 
time to progression was 4.8 months and median overall survival 8.1 months (Bellmunt et al., 
2011).  
In a multicentre phase II trial of sorafenib as second-line therapy in patients with metastatic 
urothelial carcinoma, there were no objective responses to therapy. The 4-month 
progression-free survival rate was 9.5%, and the overall survival was 6.8 months (Dreicer et 
al., 2009). 
Choueiri and colleagues conducted a double-blind randomized trial in which patients with 
metastatic bladder cancer and as many as three previous chemotherapy regimens received 
intravenous docetaxel with or without vandetanib. The results demonstrated that the 
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addition of vandetanib to second-line docetaxel did not result in significant improvements 
in progression-free survival, overall survival or response rates (Choueiri et al., 2011). 
The final results of a phase II study of everolimus in metastatic urothelial cell carcinoma 
have been presented at 2011 ASCO (American Society of Clinical Oncology) Annual 
Meeting. It was demonstrated that everolimus has clinical activity in patients with advanced 
urothelial bladder cancer.  For the thirty-seven evaluable patients, the median progression-
free survival was 3.3 months, and the median overall-survival was 10.5 months. Some side 
effects possibly related to everolimus were observed, namely anemia, infection, 
hyperglycemia, lymphopenia, hypophosphatemia and fatigue (Milowsky et al., 2011). 
Dovitinib (TKI258) is an oral investigational drug that inhibits angiogenic factors, including 
FGFR and VEGFR. A multicenter, open-label phase II trial of dovitinib in advanced 
urothelial carcinoma patients with either mutated or wild-type FGFR3 is currently 
underway (Milowsky et al., 2011). 
4.3 Phase III studies 
A randomized double-blinded phase III study comparing gemcitabine, cisplatin, and 
bevacizumab to gemcitabine, cisplatin, and placebo in patients with advanced urothelial 
carcinoma is open to enrollment. The primary end point is to compare the overall survival of 
patients with advanced urothelial carcinoma treated with gemcitabine hydrochloride, 
cisplatin, and bevacizumab versus gemcitabine hydrochloride, cisplatin, and placebo. The 
secondary end points are to compare the progression-free survival, the objective response 
rate and the grade 3 and greater toxicities of these regimens in the patients (Cancer and 
Leukemia Group B, 2011). 
5. Conclusion 
Bladder cancer represents a significant health problem, and the costliest type of cancer to 
treat. Although the majority of cases present as non-muscle invasive disease, the recurrence 
and progression rates are high, which demands for long-term follow-up and repeated 
interventions. Moreover, patients with advanced tumors treated by neoadjuvant or adjuvant 
regiments frequently progress and may develop chemotherapy resistance. Therefore, 
biomarkers of tumour aggressiveness and response to therapy are urgently needed, since 
the classical formulae based on stage and grade classification are insufficient to characterize 
bladder cancer. In this sense, angiogenesis, lymphangiogenesis and lymphovascular 
invasion have been described as surrogate markers of bladder cancer progression, invasion 
and metastasis, and represent potential fields of intervention. On one hand, the combined 
analysis of these biological parameters in tumor samples with the classical 
clinicopathological parameters may improve the individual characterization of bladder 
cancer, in what concerns to its clinical and prognostic course, and should allow therapeutic 
adequacy. On the other hand, the knowledge and modulating of biological phenomena 
related with bladder cancer progression may represent a significant improvement in the 
development of new drugs and in the pathological response to therapy, which ultimately 
will lead to an increase in disease-free survival and overall survival rates. 
Targeted therapy has caused dramatic changes in the treatment of other types of tumors. 
However, in bladder cancer setting, clinical trials with molecularly targeted agents have 
been few in number and largely unsuccessful. Regarding antiangiogenic and 
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antilymphangiogenic agents, these are still considered an investigational option for 
urothelial bladder cancer patients, and more results are needed to establish their roles in the 
treatment armamentarium. Research studies with anti-neovascularization drugs should not 
only provide effective agents to treat bladder cancer patients, but also predictive biomarkers 
for response to anti-neovascularization therapy, in order to implement the concept of 
personalized therapy. 
6. Acknowledgements 
We thank Nuno Sousa, from the Department of Medical Oncology of the Portuguese 
Institute of Oncology – IPO, for a critical review of the chapter. 
7. References 
Abol-Enein, H.; Tilki, D.; Mosbah, A. et al.  (2011). Does the Extent of Lymphadenectomy in 
Radical Cystectomy for Bladder Cancer Influence Disease-Free Survival? A 
Prospective Single-Center Study. European Urology, (June 2011), [Epub ahead of 
print], ISSN 0302-2838. 
Achen, M.G. & Stacker, S. (2008). Molecular Control of Lymphatic Metastasis. Annals of the 
New York Academy of Sciences, Vol.1131, pp. 225-234, ISSN 0077-8923. 
Achen, M.G.; Mann, G.B. & Stacker, S.A. (2006). Targeting lymphangiogenesis to prevent 
tumor metastasis. British Journal of Cancer, Vol.94, No.10 (May 2006), pp.1355-1360. 
Adams, R.H. & Alitalo, K. (2007). Molecular regulation of angiogenesis and 
lymphangiogenesis. Nature Reviews Cancer, Vol.8, No.6 (June 2007), pp. 464-478, 
ISSN 1474-175X. 
Afonso, J.; Santos, L.L.; Amaro, T.; Lobo, F. & Longatto-Filho, A. (2009). The aggressiveness 
of urothelial carcinoma depends to a large extent on lymphovascular invasion – the 
prognostic contribution of related molecular markers. Histopathology, Vol.55, No.5 
(November 2009), pp: 514-524, ISSN 1365-2559. 
Afonso, J.; Longatto-Filho, A.; Baltazar, F. et al. (2011). CD147 overexpression allows an 
accurate discrimination of bladder cancer patients’ prognosis, European Journal of 
Surgical Oncology, (July 2011), doi:10.1016/j.ejso.2011.06.006, ISSN 0748-7983. 
Algaba, F. (2006). Lymphovascular invasion as a prognostic tool for advanced bladder 
cancer. Current Opinion in Urology, Vol.16, No.5 (September 2006), pp. 367-371, ISSN 
1473-6586. 
Alitalo, K. & Carmeliet, P. (2002). Molecular mechanisms of lymphangiogenesis in health 
and disease. Cancer Cell. Vol.1, No.3 (April 2002), pp. 219-227, ISSN 1535-6108. 
Alitalo, K.; Tammela, T. & Petrova, T. (2005). Lymphangiogenesis in development and 
human disease. Nature, Vol.438, No.7070 (December 2005), pp. 946-953, ISSN 0028-
0836. 
Arany, Z.; Foo, S.Y.; Ma, Y. et al. (2008). HIF-independent regulation of VEGF and 
angiogenesis by the transcriptional coactivator PGC-1alpha. Nature, Vol.451, 
No.7181 (February 2008), pp. 1008-1012, ISSN 0028-0836. 
Balar, A.V.; Milowsky, M.I.; Apolo, A.B. et al. (2011). Phase II trial of gemcitabine, 
carboplatin, and bevacizumab in chemotherapy-naive patients with 
advanced/metastatic urothelial carcinoma. Proceedings of the 2011 Genitourinary 
Cancers Symposium, Abstract No 248, Orlando, Florida, USA, February 17-19, 2011. 
www.intechopen.com
 
Bladder Cancer – From Basic Science to Robotic Surgery 
 
106 
Baldwin, M.E.; Halford, M.M.; Roufail, S. et al. (2005). Vascular Endothelial Growth Factor D 
is dispensable for Development of the Lymphatic System. Molecular and Cellular 
Biology, Vol.25, No.6 (March 2005), pp. 2441-2449, ISSN 1098-5549. 
Banerji, S.; Ni, J.; Wang, S.X. et al. (1999). LYVE-1, a new homologue of the CD44 
glycoprotein, is a lymph-specific receptor for hyaluronan. The Journal of Cell Biology, 
Vol.144, No.4 (February 1999), pp. 789-801, ISSN 1540-8140. 
Bartolomeo, J.; Norden, A.D.; Drappatz, J. et al. (2010). Safety of concurrent bevacizumab 
therapy and anticoagulation in high-grade glioma patients. Proceedings of the 2010 
ASCO Annual Meeting, Abstract No 2043, Chicago, Illinois, USA, June 4-8, 2010. 
Bellmunt, J.; González-Larriba, J.L.; Prior, C. et al. (2011). Phase II study of sunitinib as first-
line treatment of urothelial cancer patients ineligible to receive cisplatin-based 
chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential 
predictive factors of activity. Annals of Oncology, (March 2011), [Epub ahead of 
print], ISSN 1569-8041. 
Bernardini, S.; Fauconnet, S.; Chabannes, E. et al. (2001). Serum levels of vascular endothelial 
growth factor as a prognostic factor in bladder cancer. The Journal of Urology, 
Vol.166, No.4 (October 2001), pp. 1275-1279, ISSN 0022-5347. 
Bochner, B.H.; Cote, R.J.; Weidner, N. et al. (1995). Angiogenesis in bladder cancer: 
relationship between microvessel density and tumor prognosis. Journal of the 
National Cancer Institute, Vol.87, No.21 (November 1995), pp. 1603-1612, ISSN 1460-
2105. 
Boere, I.A.; Hamberg, P. & Sleijfer, S. (2010). It takes two to tango: combinations of 
conventional cytotoxics with compounds targeting the vascular endothelial growth 
factor-vascular endothelial growth factor receptor pathway in patients with solid 
malignancies. Cancer Science, Vol.101, No.1 (January 2010), pp. 7-15, ISSN 1349-
7006. 
Bolenz, C.; Herrmann, E.; Bastian, P.J. et al. (2010). Lymphovascular invasion is an 
independent predictor of oncological outcomes in patients with lymph node-
negative urothelial bladder cancer treated by radical cystectomy: a multicentre 
validation trial. British Journal of Urology International, Vol.106, No.4 (August 2010), 
pp. 493-499, ISSN 2042-2997. 
Brusselmans, K.; Bono, F.; Collen, D. et al. (2005). A novel role for vascular endothelial 
growth factor as an autocrine survival factor for embryonic stem cells during 
hypoxia. The Journal of Biological Chemistry, Vol.280, No.5 (February 2005), pp. 3493-
3499, ISSN 1083-351X. 
Cancer and Leukemia Group B (2011). CALGB90601 A Randomized Double-Blinded Phase 
III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitaine, 
Cisplatin, and Placebo in Patients with Advanced Transitional Cell Carcinoma, In: 
University of Colorado Hospital, 08.07.2010, Available from: 
 http://www.uch.edu/ClinicalTrials/clinical-trials-detail/?id=117 
Cao, Y. (2005). Emerging mechanisms of tumour lymphangiogenesis and lymphatic 
metastasis. Nature Reviews Cancer, Vol.5, No.9 (September 2005), pp. 735-743, ISSN 
1474-175X. 
Carmeliet, P. & Jain, R.K. (2000). Angiogenesis in cancer and other diseases. Nature, Vol.407, 
No.6801 (September 2000), pp. 249-257, ISSN 0028-0836. 
www.intechopen.com
Angiogenesis, Lymphangiogenesis and Lymphovascular  
Invasion: Prognostic Impact for Bladder Cancer Patients 
 
107 
Carmeliet, P. (2005). VEGF as a Key Mediator of Angiogenesis in Cancer. Oncology, Vol.69, 
No.3 (November 2005) pp. 4-10, ISSN 1423-0232. 
Carmeliet, P.; Ferreira, V.; Breier, G. et al. (1996). Abnormal blood vessel development and 
lethality in embryos lacking a single VEGF allele. Nature, Vol.380, No.6573 (April 
1996), pp. 435-439, ISSN 0028-0836. 
Chan, E.S.; Patel, A.R.; Larchian, W.A. & Heston, W.D. (2011). In vivo targeted contrast 
enhanced micro-ultrasound to measure intratumor perfusion and vascular 
endothelial growth factor receptor 2 expression in a mouse orthotopic bladder 
cancer model. The Journal of Urology, Vol.185, No.6 (June 2011), pp. 2359-2365, ISSN 
0022-5347. 
Chaudhary, R.; Bromley, M.; Clarke, N.W. et al. (1999). Prognostic relevance of micro-vessel 
density in cancer of the urinary bladder. Anticancer Research, Vol.19, No.4C (July-
August 1999), pp. 3479-3484, ISSN 1791-7530. 
Chikazawa, M.; Inoue, K.; Fukata, S.; Karashima, T. & Shuin, T. (2008). Expression of 
angiogenesis-related genes regulates different steps in the process of tumor growth 
and metastasis in human urothelial cell carcinoma of the urinary bladder. 
Pathobiology, Vol.75, No.6 (December 2008), pp.335-345, ISSN 1423-0291. 
Chiong, E.; Lee, I.L.; Dadbin, A. et al. Effects of mTOR inhibitor everolimus (RAD001) on 
bladder cancer cells. Clinical Cancer Research, Vol.17, No.9 (May 2011), pp. 2863-
2873, ISSN 1557-3265. 
Cho, K.S.; Seo, H.K.; Joung, J.Y. et al. (2009). Lymphovascular invasion in transurethral 
resection specimens as predictor of progression and metastasis in patients with 
newly diagnosed T1 bladder urothelial cancer. The Journal of Urology, Vol.182, No.6 
(December 2009), pp.2625-2630, ISSN 0022-5347. 
Choueiri, T.K.; Vaishampayan U.N.; Yu, E.Y. et al. (2011). A double-blind randomized trial 
of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated 
advanced urothelial cancer. Proceedings of the 2011 Genitourinary Cancers Symposium, 
Abstract LBA239, Orlando, Florida, USA, February 17-19, 2011. 
Clark, P.E. (2009). Neoadjuvant versus adjuvant chemotherapy for muscle-invasive bladder 
cancer. Expert Review of Anticancer Therapy, Vol.9, No.6 (June 2009), pp. 821-830, 
ISSN 1473-7140. 
Cohen, M.H.; Gootenberg, J.; Keegan, P. & Pazdur, R. (2007). FDA drug approval summary: 
Bevacizumab plus FOLFOX4 as second-line treatment of colorectal cancer. The 
Oncologist, Vol.12, No.3 (March 2007), pp. 356-361, ISSN 1549-490X. 
Cook, K.M. & Figg, W.D. (2010). Angiogenesis inhibitors: current strategies and future 
prospects. CA: A Cancer Journal for Clinicians, Vol.60, No.4 (July-August 2010), pp. 
222-243, ISSN 1542-4863. 
Crew, J.P.; O’Brien, T.; Bicknell, R. et al. (1999). Urinary vascular endothelial growth factor 
and its correlation with bladder cancer recurrence rates. The Journal of Urology, 
Vol.161, No.3 (March 1999), pp. 799-804, ISSN 0022-5347. 
Crew, J.P.; O’Brien, T.; Bradburn, M. et al. (1997). Vascular endothelial growth factor is a 
predictor of relapse and stage progression in superficial bladder cancer. Cancer 
Research, Vol.57, No.23 (December 1997), pp. 5281-5285, ISSN 1538-7445. 
Da, M.X.; Wu, Z. & Tian, H.W. (2008). Tumor lymphangiogenesis and lymphangiogenic 
growth factors. Archives of Medical Research, Vol.39, No.4 (May 2008), pp. 365-372, 
ISSN 0188-4409. 
www.intechopen.com
 
Bladder Cancer – From Basic Science to Robotic Surgery 
 
108 
Detmar, M. & Hirakawa, S. (2002). The Formation of Lymphatic Vessels and Its Importance 
in the Setting of Malignancy. The Journal of Experimental Medicine, Vol.196, No.6 
(September 2002), pp. 713-718, ISSN 1540-9538. 
Dickinson, A.J.; Fox, S.B.; Persad, R.A. et al. (1994). Quantification of angiogenesis as an 
independent predictor of prognosis in invasive bladder carcinomas. British Journal 
of Urology International, Vol.74, No.6 (December 1994), pp. 762-766, ISSN 2042-2997. 
Dreicer, R.; Li, H.; Stein, M. et al. (2009). Phase 2 trial of sorafenib in patients with advanced 
urothelial cancer: a trial of the Eastern Cooperative Oncology Group. Cancer, 
Vol.115, No.18 (September 2009), pp. 4090-4095, ISSN 1097-0142. 
Durkan, G.C.; Nutt, J.E.; Rajjayabun, P.H. et al. (2001). Prognostic significance of matrix 
metalloproteinase-1 and tissue inhibitor of metalloproteinase-1 in voided urine 
samples from patients with transitional cell carcinoma of the bladder. Clinical 
Cancer Research, Vol.7, No.11 (November 2001), pp. 3450-3456, ISSN 1557-3265.  
Egami, K.; Murohara, T.; Shimada, T. et al. (2003). Role of host angiotensin II type 1 receptor 
in tumor angiogenesis and growth. The Journal of Clinical Investigation, Vol.112, No.1 
(July 2003), pp. 67-75, ISSN 0021-9738. 
Fechner, G.; Classen, K.; Schmidt, D.; Hauser, S. & Müller, S.C. (2009). Rapamycin inhibits in 
vitro growth and release of angiogenetic factors in human bladder cancer. Urology, 
Vol.73, No.3 (March 2009), pp. 665-668 (discussion 668-669), ISSN 0090-4295. 
Fernández, M.I.; Bolenz, C.; Trojan, L. et al. (2007). Prognostic Implications of 
Lymphangiogenesis in Muscle-Invasive Transitional Cell Carcinoma of the 
Bladder. European Urology, Vol.53, No.3 (March 2008), pp.571-578, ISSN 0302-2838. 
Ferrara, N. (2004). Vascular endothelial growth factor: basic science and clinical progress. 
Endocrine Reviews, Vol.25, No.4 (August 2004), pp. 581-611, ISSN 1945-7189. 
Ferrara, N. (2005). VEGF as a Therapeutic Target in Cancer. Oncology, Vol. 69, No.3 
(November 2005), pp. 11-16, ISSN 1423-0232. 
Ferrara, N.; Carver-Moore, K.; Chen, H. et al. (1996). Heterozygous embryonic lethality 
induced by targeted inactivation of the VEGF gene. Nature, Vol.380, No.6573 (April 
1996), pp. 439-442, ISSN 0028-0836. 
Flaig, T.W.; Su, L.J.; McCoach, C. et al. (2009). Dual epidermal growth factor receptor and 
vascular endothelial growth factor receptor inhibition with vandetanib sensitizes 
bladder cancer cells to cisplatin in a dose- and sequence-dependent manner. British 
Journal of Urology International, Vol.103, No.12 (June 2009), pp. 1729-1737, ISSN 
2042-2997. 
Folkman, J. (2003). Angiogenesis inhibitors: a new class of drugs. Cancer Biology & Therapy, 
Vol.2, No.4 Suppl 1 (July-August 2003), pp. S127-S133, ISSN 1555-8576. 
Fong, G.H.; Zhang, L.; Bryce, D.M. & Peng, J. (1999). Increased hemangioblast commitment, 
not vascular disorganization, is the primary defect in flt-1 knock-out mice. 
Development, Vol.126, No.13 (July 1999), pp. 3015-3025, ISSN 1477-9129. 
François, M.; Caprini, A.; Hosking, B. et al. (2008). Sox18 induces development of the 
lymphatic vasculature in mice. Nature, Vol.456, No.7222 (December 2008), pp. 643-
647, ISSN 0028-0836. 
Gallagher, D.J.; Milowsky, M.I.; Gerst, S.R. et al. (2010). Phase II study of sunitinib in 
patients with metastatic urothelial cancer. Journal of Clinical Oncology, Vol.28, No.8 
(March 2010), pp. 1373-1379, ISSN 1527-7755. 
www.intechopen.com
Angiogenesis, Lymphangiogenesis and Lymphovascular  
Invasion: Prognostic Impact for Bladder Cancer Patients 
 
109 
Galsky, M.D. (2010). Integrating antiangiogenic therapy for advanced urothelial carcinoma: 
rationale for a phase II study of gemcitabine, cisplatin, and sunitinib. Community 
Oncology, Vol.7, No.11 (November 2010), pp. 500-504, ISSN 1548-5315. 
Garcia, J.A. & Danielpour, D. (2008). Mammalian target of rapamycin inhibition as a 
therapeutic strategy in the management of urologic malignancies. Molecular Cancer 
Therapeutics, Vol.7, No.6 (June 2008), pp. 1347-1354, ISSN 1538-8514. 
Gilbert, S.M. (2008). Separating surgical quality from causality-gaining perspective in the 
debate on lymph node count and extent of lymphadenectomy. Cancer, Vol.112, No. 
(June 2008), pp. 2331-2233, ISSN 1097-0142. 
Goddard, J.C.; Sutton, C.D.; Furness, P.N.; O’Byrne, K.J. & Kockelbergh, R.C. (2003). 
Microvessel Density at Presentation Predicts Subsequent Muscle Invasion in 
Superficial Bladder Cancer. Clinical Cancer Research, Vol.9, No.7 (July 2003), pp. 
2583-2586, ISSN 1557-3265. 
Grossfeld, G.D.; Ginsberg, D.A.; Stein, J.P. et al. (1997). Thrombospondin-1 expression in 
bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor 
progression. Journal of the National Cancer Institute, Vol.89, No.3 (February 1997), pp. 
219-227, ISSN 1460-2105. 
Hahn, N.M.; Stadler, W.M.; Zon, R.T. et al. (2011). Phase II trial of cisplatin, gemcitabine, 
and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier 
Oncology Group GU 04-75. Journal of Clinical Oncology, Vol.29, No.12 (April 2011), 
pp. 1525-1530, ISSN 1527-7755. 
Hansel, D.E.; Platt, E.; Orloff, M. et al. (2010). Mammalian target of rapamycin (mTOR) 
regulates cellular proliferation and tumor growth in urothelial carcinoma. American 
Journal of Pathology, Vol.176, No.6 (June 2010), pp. 3062-3072, ISSN 0002-9440. 
Herr, H.; Lee, C.; Chang, S.; Lerner, S. & Bladder Cancer Collaborative Group (2004). 
Standardization of radical cystectomy and pelvic lymph node dissection for 
bladder cancer: a Collaborative Group report. The Journal of Urology, Vol.171, No.5 
(May 2004), pp. 1823-1828, ISSN 0022-5347. 
Herrmann, E.; Eltze, E.; Bierer, S. et al. (2007). VEGF-C, VEGF-D and Flt-4 in transitional 
bladder cancer: relationships to clinicopathological parameters and long-term 
survival. Anticancer Research, Vol.27, No.5A (September-October 2007), pp. 3127-
3133, ISSN 1791-7530. 
Hirakawa, S.; Kodama, S.; Kunstfeld, R. et al. (2005). VEGF-A induces tumor and sentinel 
lymph node lymphangiogenesis and promotes lymphatic metastasis. The Journal of 
Experimental Medicine, Vol.201, No.7 (April 2005), pp. 1089-1099, ISSN 1540-9538. 
Holopainen, T.; Bry, M.; Alitalo, K. & Saaristo, A. (2011). Perspectives on lymphangiogenesis 
and angiogenesis in cancer. Journal of Surgical Oncology, Vol.103, No.6 (May 2011), 
pp. 484-488, ISSN 1096-9098. 
Huber, S.; Bruns, C.J.; Schmid, G. et al. (2007). Inhibition of the mammalian target of 
rapamycin impedes lymphangiogenesis. Kidney International, Vol.71, No.8 (April 
2007), pp. 771-777, ISSN 0085-2538. 
Hurwitz, H.I.; Saltz, L.B.; Van Cutsem, E. et al. (2011). Venous thromboembolic events with 
chemotherapy plus bevacizumab: a pooled analysis of patients in randomized 
phase II and III studies. Journal of Clinical Oncology, Vol.29, No.13 (May 2011), pp. 
1757-1764, ISSN 1527-7755.  
www.intechopen.com
 
Bladder Cancer – From Basic Science to Robotic Surgery 
 
110 
Inoue, K.; Slaton, J.W.; Karashima, T. et al. (2000). The prognostic value of angiogenesis 
factor expression for predicting recurrence and metastasis of bladder cancer after 
neoadjuvant chemotherapy and radical cystectomy. Clinical Cancer Research, Vol.6, 
No.12 (December 2000), pp. 4866-4873, ISSN 1557-3265. 
Iyer, G.; Milowsky, M.I. & Bajorin, D.F. (2010). Novel strategies for treating relapsed/ 
refractory urothelial carcinoma. Expert Review of Anticancer Therapy, Vol.10, No.12 
(December 2010), pp. 1917-1932, ISSN 1473-7140. 
Jaeger, T.M.; Weidner, N. & Chew, K. (1995). Tumor angiogenesis correlates with lymph 
node metastases in invasive bladder cancer. The Journal of Urology, Vol.154, No.1 
(July 1995), pp. 69-71, ISSN 0022-5347. 
Jain, R.K. & Carmeliet, P.F. (2001). Vessels of death or life. Scientific American, Vol. 285, No.6 
(December 2001), pp. 38-45, ISSN 0036-8733. 
Jain, R.K. & Fenton, B.T. (2002). Intratumoral lymphatic vessels: a case of mistaken identity 
or malfunction? Journal of the National Cancer Institute, Vol.94, No.6 (March 2002), 
pp. 417-421, ISSN 1460-2105. 
Jeon, S.H.; Lee, S.J. & Chang, S.G. (2001). Clinical significance of urinary vascular endothelial 
growth factor in patients with superficial bladder tumors. Oncology Reports, Vol.8, 
No.6 (November-December 2001), pp. 1265-1267, ISSN 1791-2431. 
Ji, R.C. (2009). Lymph node lymphangiogenesis: a new concept for modulating tumor 
metastasis and inflammatory process. Histology and Histopathology, Vol.24, No.3 
(March 2009), pp. 377-384, ISSN 1699-5848. 
Kaipainen, A.; Korhonen, J.; Mustonen, T. et al. (1995). Expression of the fms-like tyrosine 
kinase 4 gene becomes restricted to lymphatic endothelium during development. 
Proceedings of the National Academy of Sciences USA, Vol.92, No.8 (April 1995), pp. 
3566-3570, ISSN 0027-8424. 
Karkkainen, M.J.; Haiko, P.; Sainio, K. et al. (2004). Vascular endothelial growth factor C is 
required for sprouting of the first lymphatic vessels from embryonic veins. Nature 
Immunology, Vol.5, No.1 (January 2004), pp.74-80, ISSN 1529-2908. 
Karl, A.; Carroll, P.R.; Gschwend, J.E. et al. (2009). The impact of lymphadenectomy and 
lymph node metastasis on the outcomes of radical cystectomy for bladder cancer. 
European Urology, Vol.55, No.4 (April 2009), pp. 826-35, ISSN 0302-2838. 
Kaufman, D.; Raghavan, D.; Carducci, M. et al. (2000). Phase II trial of gemcitabine plus 
cisplatin in patients with metastatic urothelial cancer. Journal of Clinical Oncology, 
Vol.18, No.9 (May 2000), pp. 1921-1927, ISSN 1527-7755. 
Kaufman, D.S.; Shipley, W.U. & Feldman, A.S. (2009). Bladder Cancer. The Lancet, Vol.374, 
No 9685, (July 2009), pp. 239-49, ISSN 0140-6736. 
Kerbel, R.S. (2000). Tumor angiogenesis: past, present and the near future. Carcinogenesis, 
Vol.21, No.3 (March 2000), pp. 505-515, ISSN 1460-2180. 
Kobayashi, S.; Kishimoto, T.; Kamata, S. et al. (2007). Rapamycin, a specific inhibitor of the 
mammalian target of rapamycin, suppresses lymphangiogenesis and lymphatic 
metastasis. Cancer Science, Vol.98, No.5 (May 2007), pp. 726-733, ISSN 1349-7006. 
Lassau, N.; Koscielny, S.; Chami, L. et al. (2011). Advanced hepatocellular carcinoma: early 
evaluation of response to bevacizumab therapy at dynamic contrast-enhanced US 
with quantification - preliminary results. Radiology, Vol.258, No.1 (January 2011), 
pp. 291-300, ISSN 1527-1315. 
www.intechopen.com
Angiogenesis, Lymphangiogenesis and Lymphovascular  
Invasion: Prognostic Impact for Bladder Cancer Patients 
 
111 
Laurence A.D. (2006). Location, movement and survival: the role of chemokines in 
haematopoiesis and malignancy. British Journal of Haematology, Vol. 132, No.3 
(February 2006), pp. 255-267, ISSN 0007-1048. 
Leissner, J.; Koeppen, C. & Wolf, H.K. (2003). Prognostic significance of vascular and 
perineural invasion in urothelial bladder cancer treated with radical cystectomy. 
The Journal of Urology, Vol.169, No.3 (March 2003), pp. 955-960, ISSN 0022-5347. 
Li, Y.; Yang, X.; Su, L.J. & Flaig, T.W. (2011). Pazopanib synergizes with docetaxel in the 
treatment of bladder cancer cells. Urology, Vol.78, No.1 (July 2011), pp. 233.e7-
233.e13, ISSN 0090-4295. 
Loges, S.; Mazzone, M.; Hohensinner, P. & Carmeliet, P. (2009). Silencing or fueling 
metastasis with VEGF inhibitors: antiangiogenesis revisited. Cancer Cell, Vol.15, 
No.3 (March 2009), pp. 167-70, ISSN 1535-6108. 
Lohela, M.; Bry, M.; Tammela, T. & Alitalo, K. (2009). VEGFs and receptors involved in 
angiogenesis versus lymphangiogenesis. Current Opinion in Cell Biology, Vol.21, 
No.2, (February 2009), pp. 154-165, ISSN 0955-0674. 
Lotan, Y.; Gupta, A.; Shariat, S.F. et al. (2005). Lymphovascular invasion is independently 
associated with overall survival, cause-specific survival, and local and distant 
recurrence in patients with negative lymph nodes at radical cystectomy. Journal of 
Clinical Oncology, Vol.23, No.27 (September 2005), pp. 6533-6539, ISSN 1527-7755. 
Ma, Y.; Hou, Y.; Liu, B. et al. (2010). Intratumoral lymphatics and lymphatic vessel invasion 
detected by D2-40 are essential for lymph node metastasis in bladder transitional 
cell carcinoma. Anatomical Record (Hoboken), Vol.293, No.11 (November 2010), pp. 
1847-1854, ISSN 1932-8494. 
Mäkinen, T.; Jussila, L.; Veikkola, T. et al. (2001). Inhibition of lymphangiogenesis with 
resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. 
Nature Medicine, Vol.7, No.2 (February 2001), pp.199-205, ISSN 1078-8956. 
Malmström, P.U. (2011). Bladder tumours: time for a paradigm shift? British Journal of 
Urology International, Vol.107, No.10 (May 2011), pp.1543-1545, ISSN 2042-2997. 
Martens, J-H.; Kzhyshkowska, J.; Falkowski-Hansen, M. et al. (2006). Differential expression 
of a gene signature for sacavanger/lectin receptors by endothelial cells and 
macrophages in human lymph node sinuses, the primary sites of regional 
metastasis. The Journal of Pathology, Vol.208, No.4 (March 2006), pp. 574-589, ISSN 
1096-9896 
May, M.; Herrmann, E.; Bolenz, C. et al. (2011). Association Between the Number of 
Dissected Lymph Nodes During Pelvic Lymphadenectomy and Cancer-Specific 
Survival in Patients with Lymph Node-Negative Urothelial Carcinoma of the 
Bladder Undergoing Radical Cystectomy. Annals of Surgical Oncology, Vol.18, No.7 
(July 2011), pp. 2018-2025, ISSN 1534-4681. 
McCormack, F.X.; Inoue, Y.; Moss, J. et al. (2011). Efficacy and safety of sirolimus in 
lymphangioleiomyomatosis. The New England Journal of Medicine, Vol.364, No.17 
(April 2011), pp. 1595-1606, ISSN 1533-4406. 
Milowsky, M.I.; Carlson, L.; Shi, M.M. et al. (2011). A multicenter, open-label phase II trial of 
dovitinib (TKI258) in advanced urothelial carcinoma patients with either mutated 
or wild-type FGFR3. Proceedings of the 2011 Genitourinary Cancers Symposium, 
Abstract TPS186, Orlando, Florida, USA, February 17-19, 2011. 
www.intechopen.com
 
Bladder Cancer – From Basic Science to Robotic Surgery 
 
112 
Milowsky, M.I.; Regazzi, A.M.; Garcia-Grossman, I.R. et al. (2011). Final results of a phase II 
study of everolimus (RAD001) in metastatic transitional cell carcinoma (TCC) of the 
urothelium. Proceedings of the 2011 Genitourinary Cancers Symposium, Abstract 4606, 
Orlando, Florida, USA, February 17-19, 2011. 
Miyata, Y.; Kanda, S.; Ohba, K. et al. (2006). Lymphangiogenesis and Angiogenesis in 
Bladder Cancer: Prognostic implications and Regulation by Vascular Endothelial 
Growth Factors-A, -C and -D. Clinical Cancer Research, Vol.12, No.3Pt1 (February 
2006), pp. 800-806, ISSN 1557-3265. 
Muller, A.; Homey, B.; Soto, H. et al. (2001). Involvement of chemokine receptors in breast 
cancer metastasis. Nature, Vol.410, No.6824 (March 2001), pp. 50-56, ISSN 0028-
0836. 
O’Brien, T.; Cranston, D.; Fuggle, S.; Bicknell, R. & Harris, A.L. (1995). Different Angiogenic 
Pathways Characterize Superficial and Invasive Bladder Cancer. Cancer Research, 
Vol.55, No.3 (February 1995), pp. 510-513, ISSN 1538-7445. 
Oliveira, P.A.; Arantes-Rodrigues, R.; Sousa-Diniz, C. et al. (2009). The effects of sirolimus 
on urothelial lesions chemically induced in ICR mice by BBN. Anticancer Research. 
Vol.29, No.8 (August 2009), pp. 3221-3226, ISSN 1791-7530. 
Oliver, G. & Detmar, M. (2002). The rediscovery of the lymphatic system: old and new 
insights into the development and biological function of the lymphatic vasculature. 
Genes & Development, Vol.16, No.7 (April 2002), pp. 773-783, ISSN 1549-5477. 
Padera, T.P.; Kadambi, A. & di Tomaso, E. (2002). Lymphatic metastasis in the absence of 
functional intratumor lymphatics. Science, Vol.296, No.5574 (June 2002), pp. 1883-
1886, ISSN 1095-9203. 
Papetti, M. & Herman, I.M. (2002). Mechanisms of normal and tumor-derived angiogenesis. 
American Journal of Physiology – Cell  Physiology, Vol. 282, No.5 (May 2002), pp. 947-
970, ISSN 1522-1563. 
Parada, B.; Reis, F.; Figueiredo, A. et al. (2011). Inhibition of bladder tumour growth by 
sirolimus in an experimental carcinogenesis model. British Journal of Urology 
International, Vol.107, No.1 (January 2011), pp. 135-143, ISSN 2042-2997. 
Patel, N.S.; Dobbie, M.S.; Rochester, M. et al. (2006). Up-regulation of endothelial delta-like 4 
expression correlates with vessel maturation in bladder cancer. Clinical Cancer 
Research, Vol.12, No.16 (August 2006), pp. 4836-4844, ISSN 1557-3265. 
Pinto, A.; Redondo, A.; Zamora, P.; Castelo, B. & Espinosa, E. (2010). Angiogenesis as a 
therapeutic target in urothelial carcinoma. Anticancer Drugs, Vol.21, No.10 
(November 2010), pp. 890-896, ISSN 1473-5741. 
Pinto-Leite, R.; Botelho, P.; Ribeiro, E.; Oliveira, P.A. & Santos, L. (2009). Effect of sirolimus 
on urinary bladder cancer T24 cell line. Journal of Experimental & Clinical Cancer 
Research, Vol.28, No.3 (January 2009), ISSN 1557-3265. 
Pries, A.R.; Höpfner, M.; le Noble, F.; Dewhirst, M.W. & Secomb, T.W. (2010). The shunt 
problem: control of functional shunting in normal and tumour vasculature. Nature 
Reviews Cancer, Vol.10, No.8 (August 2010), pp. 587-593, ISSN 1474-175X. 
Pugh, C.W. & Ratcliffe, P.J. (2003). Regulation of angiogenesis by hypoxia: role of the HIF 
system. Nature Medicine, Vol.9, No.6 (June 2003), pp. 677-684, ISSN 1078-8956. 
Quek, M.L.; Stein, J.P.; Nichols, P.W. et al. (2005). Prognostic significance of lymphovascular 
invasion of bladder cancer treated with radical cistectomy. The Journal of Urology, 
Vol.174. No.1 (July 2005), pp. 103-106, ISSN 0022-5347. 
www.intechopen.com
Angiogenesis, Lymphangiogenesis and Lymphovascular  
Invasion: Prognostic Impact for Bladder Cancer Patients 
 
113 
Riess, H.; Pelzer, U.; Opitz, B. et al. (2010). A prospective, randomized trial of simultaneous 
pancreatic cancer treatment with enoxaparin and chemotherapy: Final results of the 
CONKO-004 trial. Proceedings of the 2010 ASCO Annual Meeting, Abstract No 4033, 
Chicago, Illinois, USA, June 4-8, 2010. 
Risau W. (1997). Mechanisms of angiogenesis. Nature, Vol.386, No.6626 (April 1997), pp. 671-
674, ISSN 0028-0836. 
Rosner, M.; Hanneder, M.; Siegel, N. et al. (2008). The mTOR pathway and its role in human 
genetic diseases. Mutation Research, Vol.659, No.3 (September-October 2008), pp. 
284-292, ISSN 1383-5742.  
Saharinen, P.; Tammela, T.; Karkkainen, M. & Alitalo, K. (2004). Lymphatic vasculature: 
development, molecular regulation and role in tumor metastasis and inflammation. 
TRENDS in Immunology, Vol.25, No.7 (July 2004), pp. 387-395, ISSN 1471-4906. 
Santos, L.; Costa, C.; Pereira, S. et al. (2003). Neovascularization is a prognostic factor for 
early recurrence in T1/G2 urothelial bladder tumours. Annals of Oncology. Vol.14, 
No.9 (September 2003), pp. 1419-1424, ISSN 1569-8041. 
Sato, K.; Sasaki, R.; Ogura, Y. et al. (1998). Expression of vascular endothelial growth factor 
gene and its receptor (flt-1) gene in urinary bladder cancer. The Tohoku Journal of 
Experimental Medicine, Vol.185, No.3 (July 1998), pp. 173-184, ISSN 1349-3329. 
Schedel, F.; Pries, R.; Thode, B. et al. (2011). mTOR inhibitors show promising in vitro 
activity in bladder cancer and head and neck squamous cell carcinoma. Oncology 
Reports, Vol.25, No.3 (March 2011), pp. 763-768, ISSN 1791-2431. 
Schoppmann, S.F.; Birner, P.; Stockl, J. et al. (2002). Tumor-associated macrophages express 
lymphatic endothelial growth factors and are related to peritumoral 
lymphangiogenesis. The American Journal of Pathology, Vol.161, No.3 (September 
2002), pp. 947-956, ISSN 0002-9440. 
Seager, C.M.; Puzio-Kuter, A.M.; Patel, T. et al. (2009). Intravesical delivery of rapamycin 
suppresses tumorigenesis in a mouse model of progressive bladder cancer. Cancer 
Prevention Research (Philadelphia, Pa.), Vol. 2, No.12 (December 2009), pp.1008-1014, 
ISSN 1940-6215. 
Senger, D.R.; Galli, S.J.; Dvorak, A.M. et al. (1983). Tumor cells secrete a vascular 
permeability factor that promotes accumulation of ascites fluid. Science, Vol. 219, 
No. 4587 (February 1983), pp. 983-985, ISSN 1095-9203. 
Shalaby, F.; Rossant, J.; Yamaguchi, T.P. et al. (1995). Failure of blood-island formation and 
vasculogenesis in Flk-1-deficient mice. Nature, Vol. 376, No. 6535 (July 1995), pp. 62-
66, ISSN 0028-0836. 
Shariat, S.F.; Svatek, R.S.; Tilki, D. et al. (2010). International validation of the prognostic 
value of lymphovascular invasion in patients treated with radical cystectomy. 
British Journal of Urology International, Vol.105, No.10 (May 2010), pp. 1402-1412, 
ISSN 2042-2997. 
Shariat, S.F.; Youssef, R.F.; Gupta, A. et al. (2010). Association of angiogenesis related 
markers with bladder cancer outcomes and other molecular markers. The Journal of 
Urology, Vol.183, No.5 (May 2010), pp. 1744-1750, ISSN 0022-5347. 
Shirotake, S.; Miyajima, A.; Kosaka, T. et al. (2011). Angiotensin II type 1 receptor expression 
and microvessel density in human bladder cancer. Urology, Vol.77, No.4 (April 
2011), pp. 1009.e19-25, ISSN 0090-4295. 
www.intechopen.com
 
Bladder Cancer – From Basic Science to Robotic Surgery 
 
114 
Si, Z.C. & Liu, J. (2008). What "helps" tumors evade vascular targeting treatment? Chinese 
Medical Journal (English), Vol.121, No.9 (May 2008), pp.844-849, ISSN 0366-6999. 
Smith, J.A. & Whitmore, W.F.Jr. (1981). Regional lymph node metastasis from bladder 
cancer. The Journal of Urology. Vol.126, No.5 (November 1981), pp. 591-593, ISSN 
0022-5347. 
Stacker, S.A. & Achen, M.G. (2008). From anti-angiogenesis to anti-lymphangiogenesis: 
emerging trends in cancer therapy. Lymphatic Research and Biology, Vol.6, No.3-4, 
pp. 165-172, ISSN 1557-8585. 
Stein, J.P.; Cai, J.; Groshen, S. & Skinner, D.G. (2003). Risk factors for patients with pelvic 
lymph node metastasis following radical cystectomy with en bloc pelvic 
lymphadenectomy: concept of lymph node density. The Journal of Urology, Vol.170, 
No.1 (July 2003), pp. 35-41, ISSN 0022-5347. 
Sternberg, C.N.; Donat, S.M.; Bellmunt, J. et al. (2007). Chemotherapy for bladder cancer: 
treatment guidelines for neoadjuvant chemotherapy, bladder preservation, 
adjuvant chemotherapy, and metastatic cancer. Urology, Vol.69, No.1 (January 
2007), pp. 62-79, ISSN 0090-4295. 
Suzuki, K.; Morita, T. & Tokue, A. (2005). Vascular endothelial growth factor-C (VEGF-C) 
expression predicts lymph node metastasis of transitional cell carcinoma of the 
bladder. International Journal of Urology, Vol.12, No.2 (February 2005), pp. 152-158, 
ISSN 1442-2042. 
Swartz, M.A. (2001). The physiology of the lymphatic system. Advanced Drug Delivery 
Reviews, Vol.50, No1-2 (August 2001), pp. 3-20, ISSN 0169-409X. 
Thiele, W. & Sleeman, J.P. (2006). Tumor-induced lymphangiogenesis: a target for cancer 
therapy? Journal of Biotechnology, Vol.124, No.1 (June 2006), pp. 224-241, ISSN 0168-
1656. 
Tickoo, S.K.; Milowsky, M.I.; Dhar, N. et al. (2011). Hypoxia-inducible factor and 
mammalian target of rapamycin pathway markers in urothelial carcinoma of the 
bladder: possible therapeutic implications. British Journal of Urology International, 
Vol.107, No.5 (March 2011), pp. 844-849, ISSN 2042-2997.  
Tobler, N.E. & Detmar, M. (2006). Tumor and lymph node lymphangiogenesis – impact on 
cancer metastatis. Journal of Leukocyte Biology, Vol.80, No.4 (October 2006), pp. 691-
696, ISSN 0741-5400. 
Twardowski, P.; Stadler, W.M.; Frankel, P. et al. (2010). Phase II study of Aflibercept (VEGF-
Trap) in patients with recurrent or metastatic urothelial cancer, a California Cancer 
Consortium Trial. Urology, Vol.76, No.4 (October 2010), pp.923-926, ISSN 0090-4295. 
Van Trappen, P.O. & Pepper, M.S. (2002). Lymphatic dissemination of tumour cells and the 
formation of micrometastases. Lancet Oncology, Vol.3, No.1 (January 2002), pp. 44-
52. ISSN 1470-2045. 
Vasconcelos-Nóbrega, C.; Colaço, A.; Santos, L. et al. Experimental study of the anticancer 
effect of gemcitabine combined with sirolimus on chemically induced urothelial 
lesions. Anticancer Research, Vol.31, No.5 (May 2011), pp. 1637-1642, ISSN 1791-7530. 
Videira, P.A.; Piteira, A.R.; Cabral, M.G. et al. (2011). Effects of bevacizumab on autocrine 
VEGF stimulation in bladder cancer cell lines. Urologia Internationalis, Vol.86, No.1 
(February 2011), pp. 95-101, ISSN 1423-0399. 
von der Maase, H.; Hansen, S.W.; Roberts, J.T. et al. (2000). Gemcitabine and cisplatin versus 
methotrexate, vinblastine, doxorubicin and cisplatin in advanced or metastatic 
www.intechopen.com
Angiogenesis, Lymphangiogenesis and Lymphovascular  
Invasion: Prognostic Impact for Bladder Cancer Patients 
 
115 
bladder cancer: results of a large, randomized, multinational, multicenter, phase III 
study. Journal of Clinical Oncology, Vol.18, No.17 (September 2000), pp. 3068-3077, 
ISSN 1527-7755. 
Walz. J.; Shariat, S.F.; Suardi, N. et al. (2008). Adjuvant chemotherapy for bladder cancer 
does not alter cancer-specific survival after cystectomy in a matched case control 
study. British Journal of Urology International, Vol.101, No.11 (June 2008), pp. 1356-
1361, ISSN 2042-2997. 
Wiesner, C.; Pfitzenmaier, J.; Faldum, A. et al. (2005). Lymph node metastases in non-muscle 
invasive bladder cancer are correlated with the number of transurethral ressections 
and tumor upstaging at radical cystectomy. British Journal of Urology International, 
Vol.95, No. 3 (February 2005), pp. 301-305, ISSN 2042-2997. 
Wigle, J.T. & Oliver, G. (1999). Prox1 function is required for the development of the murine 
lymphatic system. Cell, Vol.98, No.6 (September 1999), pp. 769-778, ISSN 0092-8674. 
Wigle, J.T.; Harvey, N.; Detmar, M. et al. (2002). An essential role for Prox1 in the induction 
of the lymphatic endothelial cell phenotype. The EMBO Journal, Vol.21, No.7 (April 
2002),pp. 1505-1513, ISSN 1460-2075. 
Wiig, H.; Keskin, D. & Kalluri, R. (2010). Interaction between the extracellular matrix and 
lymphatics: consequences for lymphangiogenesis and lymphatic function. Matrix 
Biology, Vol.29, No.8 (August 2010), pp. 645-656, ISSN 0945-053X. 
Williams, S.P.; Karnezis, T.; Achen, M.G. & Stacker SA. (2010). Targeting lymphatic vessel 
functions through tyrosine kinases. Journal of Angiogenesis Research, Vol.2 (August 
2010), pp. 1-13, ISSN 2045-824X. 
Wilting, J.; Hawighorst, T.; Hecht, M.; Christ, B. & Papoutsi, M. (2005). Development of 
lymphatic vessels: tumour lymphangiogenesis and lymphatic invasion. Current 
Medicinal Chemistry, Vol.12, No.26, pp. 3043-3053, ISSN 0929-8673. 
Wright, J.L.; Lin, D.W. & Porter, M.P. (2008). The association between extent of 
lymphadenectomy and survival among patients with lymph node metastases 
undergoing radical cystectomy. Cancer, Vol.112, No.11 (June 2008), pp. 2401-2408, 
ISSN 1097-0142. 
Yang, C.C.; Chu, K.C. & Yeh, W.M. (2004). The expression of vascular endothelial growth 
factor in transitional cell carcinoma of urinary bladder is correlated with cancer 
progression. Urologic Oncology, Vol.22, No.1 (January-February 2004), pp. 1-6, ISSN 
1078-1439. 
Yang, H.; Kim, C.; Kim, M.J. et al. (2011). Soluble vascular endothelial growth factor 
receptor-3 suppresses lymphangiogenesis and lymphatic metastasis in bladder 
cancer. Molecular Cancer, Vol.10 (April 2011), pp.36, ISSN 1476-4598. 
Yoon, C.Y.; Lee, J.S.; Kim, B.S. et al. (2011). Sunitinib malate synergistically potentiates anti-
tumor effect of gemcitabine in human bladder cancer cells. Korean Journal of 
Urology, Vol.52, No.1 (January 2011), pp. 55-63, ISSN 2005-6745. 
Youssef, R.F. & Lotan, Y. (2011). Predictors of outcome of non-muscle-invasive and muscle-
invasive bladder cancer. Scientific World Journal, Vol.11 (February 2011), pp. 369-
381, ISSN 1537-744X. 
Zhou, M.; He, L.; Zu, X. et al. (2011). Lymphatic vessel density as a predictor of lymph node 
metastasis and its relationship with prognosis in urothelial carcinoma of the 
bladder. British Journal of Urology International, Vol.107, No.12 (June 2011), 1930-
1935, ISSN 2042-2997. 
www.intechopen.com
 
Bladder Cancer – From Basic Science to Robotic Surgery 
 
116 
Zu, X.; Tang, Z.; Li, Y. et al. (2006). Vascular endothelial growth factor-C expression in 
bladder transitional cell cancer and its relationship to lymph node metastasis. 
British Journal of Urology International, Vol.98, No.5 (November 2006), pp. 1090-1093, 
ISSN 2042-2997. 
www.intechopen.com
Bladder Cancer - From Basic Science to Robotic Surgery
Edited by Dr. Abdullah Canda
ISBN 978-953-307-839-7
Hard cover, 460 pages
Publisher InTech
Published online 01, February, 2012
Published in print edition February, 2012
InTech Europe
University Campus STeP Ri 
Slavka Krautzeka 83/A 
51000 Rijeka, Croatia 
Phone: +385 (51) 770 447 
Fax: +385 (51) 686 166
www.intechopen.com
InTech China
Unit 405, Office Block, Hotel Equatorial Shanghai 
No.65, Yan An Road (West), Shanghai, 200040, China 
Phone: +86-21-62489820 
Fax: +86-21-62489821
This book is an invaluable source of knowledge on bladder cancer biology, epidemiology, biomarkers,
prognostic factors, and clinical presentation and diagnosis. It is also rich with plenty of up-to-date information,
in a well-organized and easy to use format, focusing on the treatment of bladder cancer including surgery,
chemotherapy, radiation therapy, immunotherapy, and vaccine therapy. These chapters, written by the experts
in their fields, include many interesting, demonstrative and colorful pictures, figures, illustrations and tables.
Due to its practicality, this book is recommended reading to anyone interested in bladder cancer.
How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following:
Julieta Afonso, Lúcio Lara Santos and Adhemar Longatto-Filho (2012). Angiogenesis, Lymphangiogenesis and
Lymphovascular Invasion: Prognostic Impact for Bladder Cancer Patients, Bladder Cancer - From Basic
Science to Robotic Surgery, Dr. Abdullah Canda (Ed.), ISBN: 978-953-307-839-7, InTech, Available from:
http://www.intechopen.com/books/bladder-cancer-from-basic-science-to-robotic-surgery/angiogenesis-
lymphangiogenesis-and-lymphovascular-invasion-prognostic-impact-for-bladder-cancer-pati
© 2012 The Author(s). Licensee IntechOpen. This is an open access article
distributed under the terms of the Creative Commons Attribution 3.0
License, which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
